Qiqi Chen1, Junfeng Shi1, Aihua Fei1, Feilong Wang1, Shuming Pan1, Weiwei Wang2. 1. Department of Emergency, Xinhua Hospital, Shanghai Jiaotong University Medical College Shanghai, China. 2. Department of Clinical Laboratory, Xin Hua Hospital, Shanghai Jiaotong University School of Medicine Shanghai 200092, China.
Abstract
BACKGROUND: Neutrophil CD64 has been shown to be a promising biomarker for bacterial infection and sepsis identification. However, the prognostic value of CD64 in predicting the likelihood of survival for patients in intensive care unit (ICU) is unclear. METHODS: A total of 797 patients in the ICU of Xin-Hua Hospital, Shanghai, China were enrolled. We determined the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores from these patients and collected blood samples to measure the levels of neutrophil CD64, thyroid hormone and C-reactive protein (CRP). We assessed the association between APACHE II scores or these biomarkers and mortality of patients in the ICU. Receiver operating characteristic (ROC) curves were generated and the Area Under the Curve (AUC) for each indicator was determined. RESULTS: The AUC for CD64 was 0.752 ± 0.026, which was higher than that of FT3 (0.696 ± 0.028) and CRP (0.672 ± 0.026). APACHE II scores had the highest AUC (0.872 ± 0.018). The level of neutrophil CD64 expression positively associated with CRP and APACHE II, and negatively correlated with FT3. Multiple regression analysis revealed that APACHE II scores (Standard β value = 0.183, P < 0.001), CD64 (Standard β value = 0.518, P < 0.001) or log (CRP) (Standard β value = 1.203, P < 0.001) independently predicted ICU mortality. CONCLUSION: CD64 had the greatest power for predicting ICU mortality other than APACHE II scores. This result indicates that CD64 may be used as a biomarker to in combination with the use of APACHE II scores to improve the accuracy of predicting mortality outcome for patients in the ICU.
BACKGROUND: Neutrophil CD64 has been shown to be a promising biomarker for bacterial infection and sepsis identification. However, the prognostic value of CD64 in predicting the likelihood of survival for patients in intensive care unit (ICU) is unclear. METHODS: A total of 797 patients in the ICU of Xin-Hua Hospital, Shanghai, China were enrolled. We determined the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores from these patients and collected blood samples to measure the levels of neutrophil CD64, thyroid hormone and C-reactive protein (CRP). We assessed the association between APACHE II scores or these biomarkers and mortality of patients in the ICU. Receiver operating characteristic (ROC) curves were generated and the Area Under the Curve (AUC) for each indicator was determined. RESULTS: The AUC for CD64 was 0.752 ± 0.026, which was higher than that of FT3 (0.696 ± 0.028) and CRP (0.672 ± 0.026). APACHE II scores had the highest AUC (0.872 ± 0.018). The level of neutrophil CD64 expression positively associated with CRP and APACHE II, and negatively correlated with FT3. Multiple regression analysis revealed that APACHE II scores (Standard β value = 0.183, P < 0.001), CD64 (Standard β value = 0.518, P < 0.001) or log (CRP) (Standard β value = 1.203, P < 0.001) independently predicted ICU mortality. CONCLUSION:CD64 had the greatest power for predicting ICU mortality other than APACHE II scores. This result indicates that CD64 may be used as a biomarker to in combination with the use of APACHE II scores to improve the accuracy of predicting mortality outcome for patients in the ICU.
Authors: W A Knaus; J R Le Gall; D P Wagner; E A Draper; P Loirat; R A Campos; D J Cullen; M K Kohles; P Glaser; C Granthil; P Mercier; F Nicolas; P Nikki; B Shin; J V Snyder; F Wattel; J E Zimmerman Journal: Lancet Date: 1982-09-18 Impact factor: 79.321
Authors: Pak C Ng; Geng Li; Kit M Chui; Winnie C W Chu; Karen Li; Raymond P O Wong; Kai W Chik; Eric Wong; Tai F Fok Journal: Pediatr Res Date: 2004-09-15 Impact factor: 3.756
Authors: J Burgos; I Los-Arcos; D Álvarez de la Sierra; V Falcó; A Aguiló; I Sánchez; B Almirante; M Martinez-Gallo Journal: Eur J Clin Microbiol Infect Dis Date: 2016-05-30 Impact factor: 3.267
Authors: N Vicente López; R Forés Cachón; R Iranzo Valero; A Lerma Verdejo; E Múñez Rubio; A Royuela Vicente; A Ramos Martínez Journal: Rev Esp Quimioter Date: 2018-10-31 Impact factor: 1.553
Authors: Ata Mahmoodpoor; Seyedpouya Paknezhad; Kamran Shadvar; Hadi Hamishehkar; Ali Akbar Movassaghpour; Sarvin Sanaie; Ali Akbar Ghamari; Hassan Soleimanpour Journal: Anesth Pain Med Date: 2018-12-05
Authors: Heba E Hashem; Sherin A El Masry; Amira M Mokhtar; Eman A Ismail; Noureldin M Abdelaal Journal: Biomed Res Int Date: 2020-08-07 Impact factor: 3.411